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R E S U M O
Introdução: A Doença de Behçet (DB) é uma doença crónica rara de etiologia desconhecida. Estudos
anteriores mostram que um desequilíbrio no balanço pró-oxidante/antioxidante é importante para a sua
patogénese. Por outro lado, a ceruloplasmina (CP) é uma proteína de fase aguda expressa à superfície de
linfócitos do sangue periférico de humanos (CPL), com actividade antioxidante e com um papel relevante
no metabolismo do ferro (Fe).
Objectivos: Estudo da expressão da CPL em indivíduos com DB.
Material e Métodos: Mediu-se a CP sérica e a CPL em doentes com DB (n=10) e controlos (n=10), utilizando
técnicas de nefelometria e citometria de fluxo, respectivamente. Adicionalmente, determinaram-se
parâmetros hematológicos, marcadores bioquímicos séricos do metabolismo do Fe [Fe, ferritina,
transferrina, capacidade total de fixação do Fe, saturação de transferrina] e marcadores inespecíficos de
inflamação [proteína C reactiva (PCR) e β2-microglobulina] em todos os indivíduos.
Resultados: Apesar de não existirem diferenças significativas entre os dois grupos relativamente à CP sérica,
observou-se nos doentes uma diferença significativa na CPL devido essencialmente ao decréscimo
significativo da expressão da CP à superfície dos linfócitos CD3-CD56+. Contudo, a análise comparativa da
CPL entre indivíduos com DB medicados com azatioprina e não medicados, mostrou a existência de uma
diminuição significativa da CPL nos indivíduos tratados com este medicamento.
Conclusões: Os resultados deste estudo sugerem que o decréscimo da CPL verificado nos doentes com
DB está associada a um efeito da medicação e não à fisiopatologia desta doença.
Palavras-chave: Doença de Behçet; Ceruloplasmina; Balanço pró-oxidante/antioxidante; Linfócitos;
Azatioprina.
A B S T R A C T
Introduction: Behçet’s disease (BD) is a rare chronic inflammatory disorder of unknown aetiology. Ho-
wever, it has been postulated that a dysregulation of the prooxidant/antioxidant balance may be impor-
tant to its pathogenesis. Ceruloplasmin (CP) is an acute phase protein expressed at the surface of periphe-
ral blood lymphocytes (PBL) with antioxidant properties and with a relevant role in iron (Fe) metabolism. 
Objectives: To study CP expression at the surface of PBL (PBLCP) in patients with BD.
Material and Methods: We measured serum CP and PBLCP obtained from BD patients (n=10) and res-
pective controls (n=10) using nephelometry and flow cytometry techniques, respectively. Additionally,
haematological parameters, biochemical Fe metabolism markers [serum Fe, serum ferritin, serum trans-
ferrin, total Fe binding capacity (TIBC), transferrin saturation] and non-specific markers of inflammation
[serum C reactive protein (CRP), β2-microglobulin] were measured in all individuals.
Results: Despite the absence of significant differences between the two study groups when comparing
serum CP, a significant difference in PBLCP was found in BD patients mainly due to a significant decrease
of CP expression at the surface of CD3-CD56+ lymphocytes. Also, a significant decrease of PBLCP was ob-
served in patients treated with azathioprine compared to patients that were not being treated with this
drug.
Conclusions: According to this study, we suggest that the significant decrease of PBLCP observed in BD
patients might be due to azathioprine treatment and not directly related to the pathophysiology of BD. 
Key-Words: Behçet’s disease; Ceruloplasmin; Prooxidant/antioxidant Balance; Lymphocytes; Azathio-
prine.
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Introduction
Behçet’s disease (BD) is a rare chronic vasculitis of
unclear aetiology.1 BD is characterized by recurrent
oral and genital ulcers, skin and ocular lesions
(uveitis and retinal vasculitis). Other manifestati-
ons include arthritis, thrombophlebitis, arterial le-
sions (arterial occlusion and aneurysm), central
nervous system (CNS) involvement and gastroin-
testinal ulcerations.2
Since there is no specific laboratory marker for
BD, its diagnosis still remains clinical. Therefore,
the diagnostic criteria proposed by the «Internatio-
nal Study Group of Behçet’s Disease» (ISGBD) in
1990 are widely accepted.3 According to these cri-
teria BD patients are characterized as having re-
current oral ulcers and, at least, two of the following
symptoms: recurrent genital ulcers, eye lesions,
skin lesions or positive pathergy test. 
Although the aetiology of BD remains unknown,
several reports suggest an excessive production of
reactive oxygen species (ROS) by activated neutrop-
hils. Also, a diminished enzymatic antioxidant ac-
tivity might have a crucial role in tissue lesions cha-
racteristic of this disease.4,5 Particularly, it has been
described in BD patients an increase in the plasma
levels of some oxidative stress markers such as ni-
tric oxide (NO), nitrite, nitrate6 and malondial-
dehyde (MDA),7 a final product of the lipid peroxi-
dation from ROS action. Other reports showed a
decrease in plasma glutathione peroxidase (GSH-
-Px) activity7 as well as in the activity of reduced glu-
tathione (GSH),8 suggesting a decrease of the antio-
xidant activity in these patients. Additionally, dysre-
gulation in lipid metabolism has been reported in
BD patients including the increase of lipoproteins,
lipid hydroperoxides and susceptibility to oxidati-
on of low density lipoproteins (LDL)9 associated
with a decrease of paraoxonase (PON) activity, in-
dicating the development of an endothelial
dysfunction. 
Ceruloplasmin (CP) is an abundant plasma α2-
-glicoprotein included in a family of proteins called
multicopper oxidase enzymes.10 CP contains three
types of spectroscopically distinct copper (Cu) si-
tes which incorporate 6 or 7 Cu atoms during CP
biosynthesis. Although the liver is the predominant
source of serum CP, extrahepatic CP gene expres-
sion has been demonstrated in many tissues inclu-
ding lungs, testicles and CNS.11 Recently prelimi-
nary studies by our group showed that peripheral
blood lymphocytes (PBL) are able to synthesize
CP,12 expressing it at their surface13-16 and releasing
it into the extracellular milieu.17
CP possesses an antioxidant role due to its fer-
roxidase activity in iron (Fe) metabolism.11 The oxi-
dation of ferrous ion (Fe2+) to ferric ion (Fe3+) by CP
is thought to reduce oxidative stress by preventing
the Fenton reaction in which Fe2+ generates ROS.
This reaction is also crucial for the Fe mobilisation
and release from cellular stores for uptake by the
circulating iron transport protein transferrin (Tf).18
It has been shown that humans with mutations
in the CP gene (aceruloplasminemia patients) have
Fe accumulation in the brain leading to neurode-
generation.19 Also, CP knockout mice (CP-/-) show
excessive Fe content in the brain with ageing.20
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Moreover, CP may act as an acute phase reactant
being involved in protective cellular mechanisms
mediated by the immune system (IS). Accordingly,
CP levels are increased in several clinical settings
including infection, trauma and inflammation.10
An increase in serum CP was previously repor-
ted in BD patients.4,7 However, to our knowledge
the expression of CP at surface of PBL has never
been studied in these patients. 
Objectives
The main goal of this work was to study CP expres-
sion at the surface of PBL in patients with BD.
Material and Methods
Individuals
Ten BD patients, that fulfilled the international cri-
teria proposed by the ISGBD, of both genders, with
more than 20 and less than 60 years old, were se-
lected from the Instituto Português de Reumatolo-
gia (IPR) outpatient clinic for this study (BD group).
All the assays were performed in 10 healthy blood
donors age-gender matched, recruited from the
Hospital Reynaldo dos Santos (HRS) [control (C)
group].
Disease duration was 1-29 years (11,7 ± 2,7 years,
mean ± standard error). At the time of blood col-
lection, 50% of the patients were considered acti-
ve and 50% inactive according to the clinical eva-
luation of the 4 previous weeks.
Of the ten patients, eight were receiving treat-
ment, namely oral colchicine (30% of the BD
group), azathioprine (50% of the BD group) and/or
corticosteroids (30% of the BD group). The three
patients receiving colchicine had the last intake
48h before blood collection, while in the five pati-
ents receiving azathioprine only one took it in the
same day of the blood collection. The other four
patients that were on azathioprine treatment were
medicated more than 12h before sample collec-
tion. Also, corticosteroids had been administered
more than 24h before blood collection.
All the patients in the study had typical involve-
ment including oral (90%) and genital (60%) aphta,
uveitis (40%), skin lesions (70%) and arthritis (40%). 
Collection of total peripheral blood was done
after all participants had given their informed con-
sent.
Haematological and biochemical measurements
Cell blood count were performed in EDTA collec-
ted peripheral blood from volunteers using an au-
tomated haematology counter Coulter MAXM and
included: measurement of haemoglobin concen-
tration (Hb), red cell count (RBC), packed cell vo-
lume (PCV), mean cell volume (MCV), mean cell
haemoglobin (MCH), mean cell haemoglobin con-
centration (MCHC), red cell distribution width
(RDW), white cell count (WBC) and differential
white cell count.
Serum Fe and Tf were measured using an auto-
mated analyser BM/Hitachi 911 (Boehringer Man-
nheim, Roche) by a coloured enzymatic test. Tf sa-
turation was calculated from the total iron binding
capacity (TIBC) and serum Fe values. Quantitati-
ve measurements of serum ferritin (Ft) were per-
formed by an immunometric assay using an Im-
mulite analyser. Serum CP, C reactive protein (CRP)
and β2-microglobulin (β2m) were measured by
nephelometry using a Beckman Immage analyzer.
Flow cytometry analysis of surface expression of 
ceruloplasmin in peripheral blood lymphocytes
Fresh peripheral blood cells were obtained from 
1 ml of EDTA collected peripheral blood. RBC were
lysed in lysis solution (10mM Tris, 16mM NH4Cl,
pH 7.4) for 10 min at 37°C and the remaining whi-
te blood cells were then washed in PBS supple-
mented with 0.2% of bovine serum albumin (BSA),
resuspended and plated in round-bottomed mi-
crotitre plates (Nunclon, Denmark) at 3×105
cells/well. 
Cells were stained for CP using the rabbit anti-
-human CP (DakoCytomation, Denmark) as pri-
mary antibody (Ab) followed by incubation with a
swine F(ab’)2 anti-rabbit FITC-conjugated as se-
condary Ab (DakoCytomation, Denmark). To de-
termine CP’s mean fluorescence intensity (MFI) in
specific lymphocyte subsets, monoclonal Ab
(mAb) CD4-PE, CD8-PE, CD19-PE or CD56-PE
conjugated were used separately combined with
mAb CD45-PerCP conjugated for lymphocyte ga-
ting and mAb CD3-APC conjugated for positive or
negative selection of Tcells. Non-stained cells were
used as negative control, to determine autofluores-
cence. All mAb were purchased from Pharmingen.
After staining, cells were washed twice in PBS/
/BSA solution, resuspended in FACS Flow solution
and flow cytometry analysis was performed using
a FACSCalibur (Becton&Dickinson). Analysis of
data was done using the CellQuest™ Software. 
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Results are presented in Arbitrary Units (AU) re-
sulting from the ratio between the MFI of stained
cells and the MFI of non-stained cells in the same
population. 
Statistical Analysis
All results were given as mean ± standard error (SE).
Statistical analysis was performed using the Mann-
-Whitney and Kruskall-Wallis tests. Multiple com-
parisons between groups were performed using
the Dunnett T3 Test. Values of p≤ 0, 05 were accep-
ted as statiscally significant. SPSS Base 14.0 softwa-
re was used to perform all statistical analysis (SPSS
inc. 2005).
Results
In this work, 10 patients with BD [7 women (70%)
and 3 men (30%)] and a control (C) group formed
by 10 healthy blood donors [7 women (70%) and 3
men (30%)] were studied. The age for BD group
was 42,7 ± 3,1 years old with a minimum of 23 and
a maximum of 55 years old, while for the C group
the age was 44,1 ± 3,5 years, in a range from 26 to
60 years old.
Results obtained concerning the measurement
of haematological parameters showed no signifi-
cant differences between BD and C groups. 
Despite the absence of significant differences in
serum Fe and Ft concentrations measured in both
groups, significant increases (p=0,014) in serum Tf
(298,7 ± 13,3 mg/dL vs 251,5 ± 10,7mg/dL; p=0,014)
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and TIBC (373,4 ± 16,6mg/dL vs 314,4± 13,4mg/dL)
were observed in BD patients compared to controls
(Table I). However, no significant difference was
found between BD patients and controls when
comparing concentration of CP, CRP and β2m in se-
rum (Table I). 
Additionally, results from flow cytometry analy-
sis (Figure 1) showed a significant decrease of
PBLCP from BD patients comparatively to controls
(48,4±7,7 AU vs 77,7±10,9 AU; p=0,041). This diffe-
rence was mainly due to a significant decrease
(p=0,041) of CP surface expression in CD3-CD56+
cells (NK cells) of BD patients when compared to
CD3-CD56+ cells from controls (164,3±37,5 AU vs
323,62±57,6 AU; Figure 2).
In order to understand these results, an additio-
nal comparison between PBLCP from BD patients
under treatment and PBLCP from controls was
performed. No significant differences were found
between PBLCP from patients treated with colchi-
cine (and/or corticosteroids) and PBLCP from con-
trols (data not shown). However, BD patients trea-
ted with azathioprine showed a significant decrea-
se of PBLCP (p=0,005) compared to controls (29,7
± 3,7 AU vs 77,7 ± 10,9, respectively; Figure 3). Also,
a significant decrease of PBLCP (p=0,026) was
found when comparing patients treated with
azathioprine with non-azathioprine treated pa-
tients (29,7 ± 3,7 AU vs 67,2 ±8,8 AU, respectively;
Figure 3). Moreover, no significant difference in
PBLCP was found between non-azathioprine trea-
ted patients and controls (67,2 ±8,8 AU vs 77,7 ±
10,9, respectively; Figure 3).
Discussion
Oxidative stress has been implicated in
the pathogenesis of certain disorders in-
cluding BD.21 Disturbance in the prooxi-
dant/antioxidant balance and the pro-
duction of free radicals play a significant
role in this process.4 On the other hand, Fe
metabolism and oxidative stress are cle-
arly interactive, especially under pa-
thological conditions. In fact, Fe is extre-
mely important due to its capacity of 
acting both as a donor and acceptor of
electrons.22 However, this property allows
Fe to be potentially toxic since it catalyses
the conversion of hydrogen peroxide
(H2O2) to free radicals. Proteins such as Tf
Table I. Iron metabolism and inflammatory proteins 
measured in serum from BD patients (BD group) 
and controls (C group).  
Iron Metabolism C group BD group
Parameters (Mean±SE) (Mean±SE)
Fe (µg/dL) 103,2 ± 5,7 105,3 ± 10,3
Ft (ng/dL) 68,6 ± 22,9 119,5 ± 25,1
Tf (mg/dL) * 251,5 ± 10,7 298,7 ± 13,3
TIBC (mg/dL) * 314,4 ± 13,4 373,4 ± 16,6
Inflammatory proteins
CP (mg/dL) 31,4 ± 2,2 39,9 ± 4,6
CRP (mg/dL) 0,3 ± 0,1 0,5 ± 0,1
β2-m (µg/L) 983,2 ± 68,3 1068,8 ± 64,0
Fe – iron; Ft – ferritin;Tf – transferrin;TIBC – total iron binding capacity;CP – serum Ceru-
loplasmin; CRP – C Reactive Protein; β2m – β2-microglobulin; *: p=0,014.
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and Ft help to prevent this oxidative attack by se-
questering Fe and avoiding radicals formation
and/or lipid peroxidation.23
In this study, an increase in serum Fe and Ft con-
centrations and a significant increase of serum le-
vels of Tf and TIBC were observed in the BD group
comparatively to controls (Table I). These results
suggest that the raise of Tf and Ft observed in BD
patients may be related to a possible compensa-
tory mechanism to limit oxidative stress in this di-
sease. 
During the active phase of the disease, BD is as-
sociated with many non-specific features of syste-
mic inflammation, including an increase in the le-
vel of circulating pro-inflammatory cytokines, in-
creased CRP and β2m.24 The results obtained in this
study give additional support for these previous
findings, since an increase of CRP and β2m, al-
though not significant, was found in BD patients
comparatively to controls. On the other hand, se-
rum CP is also considered an acute phase reactant.
Accordingly, an increase of CP serum concentra-
tions has already been reported in BD patients in
other studies.25 Although not statistically signifi-
cant, results obtained in this study also showed an
increase of serum CP levels in BD group compared
to controls. However, a significant decrease in
PBLCP was found in BD patients comparatively to
controls. This decrease seemed to be due to a sig-
nificant reduction of PBLCP observed in BD pa-
tients treated with azathioprine. In fact, these pa-
tients showed a significant decrease of PBLCP
when compared to non-azathioprine treated BD
patients. Furthermore, a decrease in PBLCP was
also found when comparing azathioprine treated
patients with the respective controls. Overall, these
results suggest that azathioprine treatment might
have a direct effect on CP expression at the cell sur-
face of PBL. 
Conclusions
The results obtained in this study suggest that the
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Figure 3. Mean fluorescence intensity (MFI) ratio of CP at
the surface of peripheral blood lymphocytes (PBLCP) in 
BD patients treated with azathioprine (azathioprine BD
group), non-azathioprine treated BD patients (non-azathio-
prine BD group) and control group (C group) (*: p= 0,026;
**: p= 0,005).
PBLCP
100
80
70
60
20
10
0
90
50
40
30
C group
BD group
*
M
F
I 
(A
U
)
Figure 1. Mean fluorescence intensity (MFI) ratio of CP at
the surface of peripheral blood lymphocytes (PBLCP) in BD
patients (BD group) and controls (C group) (*: p= 0,041).
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Figure 2. Mean fluorescence intensity (MFI) ratio of CP 
at the surface of lymphocyte subpopulations in BD patients
(BD group) and controls (C group). CD3+CD4+ = T helper
lymphocytes; CD3+CD8+ = T cytotoxic lymphocytes;
CD3-CD19+ = B lymphocytes; CD3-CD56+ = Natural Kil-
ler (NK) lymphocytes; CD3+CD56+ = NKT lymphocytes 
(*: p= 0,41).
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significant decrease of PBLCP found in BD patients
comparatively to controls is due to the azathiopri-
ne treatment and not related to BD. However, fur-
ther studies including a larger number of patients
are needed to fully understand the role played by
PBLCP in BD pathophysiology.
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